On September 20, 2008, The Wall Street Journal (WSJ) reported that Pfizer was going to discontinue efforts
Question:
Required
a. By stopping the development of drugs related to the treatment of heart disease, obesity, and bone health Pfizer hoped to reduce the amount spend on research and development. Relative to the level of sales, should R&D costs be considered:
■ Fixed costs or variable costs
■ Marginal costs or not
b. Were the R&D costs that Pfizer had spent in past years to develop drugs related to heart disease relevant to its decision to discontinue their future development? If they were not relevant costs, what kind of cost were they?
c. Explain how Pfizer can afford to sell drugs in Venezuela for 30 percent lower prices than it sells them for in the United States.
d. Obtain Pfizer’s annual report for 2008. Pfizer’s annual reports can be found at its website: www.pfizer.com. Calculate its operating costs as a percentage of revenue for 2006, 2007, and 2008. (The easiest way to do this is to calculate its “income from continuing operations” as a percentage of revenue, and subtract that amount from 1.0.) Does it appear that Pfizer is accomplishing its goal of reducing its cost? Show supporting computations.
Fantastic news! We've Found the answer you've been seeking!
Step by Step Answer:
Related Book For
Fundamental Managerial Accounting Concepts
ISBN: 978-0078110894
6th Edition
Authors: Edmonds, Tsay, olds
Question Posted: